# Hudson River Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hudson-river-biotechnology

- Industry: Biotechnology
- Headquarters: Netherlands
- Website: www.hudsonriverbiotechnology.com
- Total disclosed funding: $5.9M
- Latest round: Series A (Aug 5, 2021)
- Investors on record: 1

## About

Based in Wageningen, the Netherlands, and founded in 2015, Hudson River Biotechnology, also known as HRB, is an agricultural biotech company that specialized in providing CRISPR-based genome editing in plants. The company was co-founded by Rudi Ariaans and Ferdinand Los and is backed by investors led by Bridford Group in a EUR 5 million Series A funding round in August 2021. 

HRB's platform develops crop varieties with new traits, including food and ornamental crops, as well as plants used to produce high-value compounds for the pharmaceutical, food, and ingredient industries. It offers end-to-end genome editing solutions for plants, fungi, and microorganisms. The company uses genome-editing tool CRISPR, which was applied using a proprietary, validated molecular breeding workflow called TiGER, an acronym for Target identification, Guide selection, Entry into the cell, and Regeneration. The CRISPR enzyme is called MAD7, due to the low licensing costs (MAD TiGER).

HRB plans to further develop its nanotech offering and explore market opportunities, as well as accelerating its core crop-breeding business.

## Funding rounds

- Series A, Aug 5, 2021, $5.9M — Bridford Investments Ltd.

## Investors

- Bridford Investments Ltd. (https://capitalatlas.ai/funds/bridford-investments-ltd) — Series A